Gedea Biotech develops an antibiotic-free and safe local treatment of vaginal bacterial and fungal infections. Gedea is in the final stage of a clinical study in bacterial vaginosis with preliminary positive results. The first product is estimated to be CE-marked in the end of 2020 for treating and preventing bacterial vaginosis. Gedea is also executing a clinical programme for a pipeline product with dual effect on both bacterial vaginosis and vaginal candidiasis. Late 2019 Gedea received a 3M Euro grant from the Horizon-program Fast-track-to-Innovation, covering the clinical program and company activities for the upcoming 2 years. Gedea is now seeking an investment for the co-funding of the grant.
Gedea Biotech is a spin-out company from Lund University, located in Lund, Sweden.